Clinical trials: LRRK2
Parkinsons Disease (PD), LRRK2
LRRK2 (Leucine-Rich Repeat Kinase 2) Parkinson's Disease Fingerprint
The goal of this interventional monocentric study is to identify molecular and clinical markers of LRRK2-related Parkinson's disease through blood markers analysis and deep clinical phenotyping.
- Trial name
- NEU-PD (NCT07681219)
- Testing
- The interventions of the study are the study of blood biomarkers and neuroimaging and neurophysiological data
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Parkinson Disease
Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease
Parkinson's disease (PD) is a neurodegenerative disease characterized by the neurodegeneration of substance nigra pars compacta (SNpc) and the formation of alpha-synuclein protein aggregates in neurons.
- Trial name
- NCT05355064
- Testing
- Trehalose
- Volunteers
- 20 people
- Sponsor
- Neuromed IRCCS
Parkinson's Disease
Parkinson's Disease G2019S LRRK2 Genetic Testing Program
Increase awareness of the G2019S LRRK2 mutation in Parkinson's and no cost genetic testing program.
- Trial name
- NCT04919356
- Testing
- G2019S LRRK2
- Where
- United States
- Volunteers
- 836 people
- Sponsor
- Escape Bio, Inc.
Parkinson Disease
Objective, Passive Assessment of LRRK2 Carriers
The goal of this project is to identify objective, sensitive, and convenient measures for assessing early signs of Parkinson's disease in an at-risk population at home.
- Trial name
- OPAL (NCT05287620)
- Testing
- Emerald device
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Rochester
Parkinson's Disease
A Longitudinal Study in Parkinson's Disease (PD) Patients
This is a longitudinal study in patients with Parkinson's Disease (PD) carriers of a genetic mutation - substitution of gly with ser in position 2019 (G2019S) in the leucine-rich repeat kinase 2 (LRRK2) gene.
- Trial name
- NCT01730599
- Testing
- neurological exam
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Parkinson Disease
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers
The goals of this study are 1. To compare the functional effects of the LRRK2 G2385R variant among carriers with and without Parkinson's disease (PD) and non-carriers with and without PD 2.
- Trial name
- NCT04349865
- Where
- China
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene
A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease
To characterize using a participant centered decentralized (at home) study featuring wearable technology and telemedicine to study disease change over time in patients with PD caused by the G2019S mutation in the LRRK2 gene and…
- Trial name
- NCT05349019
- Testing
- Observational
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Escape Bio, Inc.
Parkinson Disease
LRRK2 G2385R Leucocyte and Urine Biomarker Study
Given the emerging evidence on LRRK2-related biomarkers, this project will focus on identifying leucocyte and urine biomarkers that are altered by the LRRK2 G2385R variant, and investigating the effects of LRRK2 kinase inhibitor…
- Trial name
- LRRK2 G2385R (NCT04436848)
- Testing
- This is a non-interventional study
- Where
- Malaysia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Parkinson Disease, PARK8, Parkinson Disease
Molecular Pathology and Neuronal Networks in LRRK2 Parkinson's Disease
Parkinson's Disease (PD) is a progressive neurodegenerative disease characterized clinically by bradykinesia, resting tremor, rigidity, and postural instability.
- Conditions
- Parkinson Disease, PARK8, Parkinson Disease, Idiopathic Parkinson Disease
- Trial name
- NCT03782753
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- King's College London
Parkinson Disease, GBA Gene Mutation
Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's Disease
Sleep disturbances are one of the most common non-motor symptoms in PD, with an estimated prevalence as high as 40-90%. Sleep disturbances (particularly sleep duration, sleep fragmentation, Rapid Eye Movement (REM) sleep behavior…
- Conditions
- Parkinson Disease, GBA Gene Mutation, Leucine-rich Repeat Kinase 2 (LRRK2) Gene Mutation
- Trial name
- NCT04387812
- Testing
- Xtrodes home PSG system
- Where
- Israel
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Parkinson's Disease
Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation
The clinical and pathological similarities between LRRK2 related parkinsonism and idiopathic Parkinson's disease (PD) indicate that monogenetic LRRK2 parkinsonism may be a paradigm for the development of Lewy bodies disease, and…
- Trial name
- EnteroLarc (NCT01618383)
- Testing
- colonoscopy or rectosigmoidoscopy
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Nantes University Hospital
Parkinson's Disease
Study to Evaluate DNL151 in Subjects With Parkinson's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL151 in subjects with Parkinson's disease.
- Trial name
- NCT04056689
- Testing
- DNL151
- Where
- 8 sites in United States, Belgium and 2 more
- Volunteers
- 36 people
- Sponsor
- Biogen
Parkinson Disease
Non-drug Treatment Study in Parkinson's Disease Patients and Healthy Volunteers to Collect Biological Samples in Order to Assess ex Vivo the Activity of Candidate Therapies and Develop Novel Analytical Methods for Biomarkers
This is a non-drug study in patients with Parkinson's Disease (PD) and healthy volunteers to process and analyze their blood and optional cerebrospinal fluid (CSF) samples ex vivo, or outside of their body, to further develop…
- Trial name
- IRIS-CLE-LRRK2 (NCT05837130)
- Testing
- Blood sample collection and an optional cerebrospinal fluid (CSF) collection, Blood sample collection
- Where
- 4 sites in France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Servier
Healthy Volunteer
Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444
The overall goal of this protocol is to evaluate the binding of caffeine to adenosine A2A receptors in the brain of participants at risk for developing PD.
- Trial name
- NCT05009199
- Testing
- [18F]MNI-444
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Invicro
Parkinson Disease
LRRK2 Mutation and Parkinson's Disease
The Leucine-Rich Repeat Kinase 2 (LRRK2) is implicated in autosomal dominant Parkinson's disease (PKD). An inhibitor for the leucine-rich repeat kinase 2 (LRRK2) is in pre-clinical development for potential use in treating…
- Trial name
- NCT01424475
- Testing
- Healthy, PKD Patients
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parkinson Disease, Prodromal Stage
Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage
The goal of this clinical trial is two-fold. First to investigate the feasibility of whether a remotely administered smartphone app can increase the volume and intensity of physical activity in daily life in individuals with a…
- Conditions
- Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases
- Trial name
- Slow-SPEED (NCT06993142)
- Testing
- Increase of physical activity volume and intensity with the use of a motivational smartphone application
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 600 people
- Sponsor
- Radboud University Medical Center
Parkinson Disease
Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics
Parkinson disease is one of the most common neurodegenerative illnesses. The disease is characterized by decrease in dopamine levels and decrease in the number of dopaminergic neurons and dopamine receptors.
- Trial name
- NCT01089283
- Where
- Israel
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Parkinson Disease
Characteristics of Parkinson s Disease Associated With the LRRK-2 Gene Mutation
This study will identify symptoms and other characteristics of Parkinson s disease that may be associated with changes in a gene called leucine-rich repeat kinase 2 (LRRK2).
- Trial name
- NCT00467090
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease
LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease
This proposal seeks to 1) determine whether there are biomarkers associated with Parkinson's disease (PD) susceptibility and/or progression in exosome-proteomes derived from PD patients versus controls, and 2) to determine if…
- Trial name
- NCT01860118
- Where
- United States
- Volunteers
- 601 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Parkinson Disease, Parkinson
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich…
- Conditions
- Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)
- Trial name
- NEULARK (NCT06680830)
- Testing
- NEU-411
- Where
- 72 sites in United States, Israel and 4 more
- Volunteers
- 150 people
- Sponsor
- Neuron23 Inc.